Smart scans and DNA tests aim to boost breast cancer remission
NCT ID NCT07565324
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tests a new approach for people with HER2-positive early breast cancer. After initial chemotherapy, if scans or DNA tests show remaining cancer, participants get a different drug combination (PLD, cyclophosphamide, trastuzumab, and pertuzumab) to try to eliminate all cancer before surgery. The goal is to see if this tailored strategy increases the chance of complete remission and reduces heart side effects. About 54 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Conditions
Explore the condition pages connected to this study.